The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Botox sales outpace forecasts

Article-Botox sales outpace forecasts

Irvine, Calif. — Sales of Botox (onabotulinumtoxinA, Allergan) climbed 16 percent in second quarter 2011 compared to the previous year, the company announced.

Revenues from sales of the drug reached $418 million, exceeding the average forecast of $397.6 million of seven analysts, the Los Angeles Times reports.

The Times quotes Gary Nachman, a senior analyst at Susquehanna International Group in New York, as saying that Botox has managed to overcome the kinds of challenges a weak economy usually presents to sales of cosmetic drugs.

“The aesthetic market has been very strong despite a challenging economy,” Mr. Nachman told the Times. “Your existing patient base won’t go away. They may time the procedures a little differently, but once they get used to looking younger, they don’t want to change that."

Allergan’s second-quarter profit rose 2.7 percent, and net income increased to $246.6 million from $240.1 million the previous year, according to the earnings report. Sales rose to $1.42 billion from $1.25 billion in 2010.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.